Detalhe da pesquisa
1.
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.
Pulm Pharmacol Ther
; 82: 102246, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562641
2.
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
Eur Respir J
; 59(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34385272
3.
Tiotropium in asthma poorly controlled with standard combination therapy.
N Engl J Med
; 367(13): 1198-207, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22938706
4.
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.
Eur Respir J
; 46(5): 1308-21, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26357963
5.
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers.
ERJ Open Res
; 7(1)2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569494
6.
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1.
ERJ Open Res
; 6(4)2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313307
7.
U-BIOPRED: evaluation of the value of a public-private partnership to industry.
Drug Discov Today
; 23(9): 1622-1634, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936248